#78 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Researchers at UC San Diego are investigating the effects of cannabis use on adolescent brain development, addressing a significant gap in pediatric cannabis research at a time when youth access and use patterns are changing across legalized states. Understanding how cannabis exposure during critical developmental periods may impact cognition, mental health, and neurological function is essential for clinicians who counsel adolescent patients and their families about substance use risks. The study’s findings could inform clinical guidelines for screening, prevention, and intervention strategies in pediatric and adolescent medicine, particularly as more young people have access to increasingly potent cannabis products. Clinicians should remain vigilant about assessing cannabis use in youth presentations of academic decline, behavioral changes, or psychiatric symptoms, and use emerging evidence to guide patient and family counseling on developmental neurotoxicity risks during adolescence.
“What we’re seeing in the developmental neuroscience literature is clear enough that I counsel all parents: the adolescent brain is still undergoing critical myelination and synaptic pruning through the mid-twenties, and cannabis use during this window carries real risks to attention, memory, and impulse control that we can’t simply wish away with anecdotal success stories. The conversation with young patients needs to be honest about this biology, not paternalistic, but grounded in what the evidence actually shows us.”
? While emerging research from institutions like UC San Diego is expanding our understanding of cannabis effects on the developing adolescent brain, clinicians should recognize that the evidence base remains incomplete and evolving, with substantial variation in study designs, exposure metrics, and outcome measures that complicate straightforward clinical recommendations. The developing brain’s particular vulnerability to cannabinoids during critical windows of maturation is biologically plausible and supported by some neuroimaging and neurocognitive findings, yet causality remains difficult to establish given confounders such as concurrent alcohol or other substance use, socioeconomic factors, and underlying psychiatric conditions that often co-occur with youth cannabis use. Clinicians should use these emerging findings to inform more targeted screening and counseling conversations with adolescent patients and families, emphasizing the precautionary principle regarding brain development while avoiding alarmism unsupported by definitive evidence. Given the legal landscape in California and elsewhere, providers should also be prepared to
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
